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Introduction
Hepatocellular carcinoma (HCC) is one of the most com-
mon malignancies worldwide and is frequently a terminal
complication of chronic inflammatory and fibrotic liver
disease (1). HCC treatment is palliative, and long-term
survival is rare. Intrahepatic metastasis is a main cause of
HCC recurrence and poor prognosis after tumor resection
(1). Chronic hepatitis B virus (HBV) infection is strongly
associated with the development of cirrhosis and HCC (1,
2). After integration of the HBV DNA into the host
genome, the expression of the viral protein HBx becomes
deregulated and is still found in transformed hepatocytes,
even in the absence of any other viral marker (2, 3).
Most efforts in the study of the role of HBx in HCC
development have focused on its involvement in the
genesis of liver carcinomas. In this regard, HBx is able to
induce HCC either alone or in synergy with c-myc or
chemical carcinogens in transgenic mice (4–6). HBx acti-
vates several signal transduction pathways that lead to
the transcriptional upregulation of a number of cellu-
lar genes, including those of growth and angiogenic fac-
tors and oncogenes (2, 7). In addition, HBx promotes
cell cycle progression, inactivates negative growth regu-
lators like p53, and facilitates the accumulation of DNA
mutations by interfering with the DNA repair machin-
ery (2). HBx is also able to interfere with apoptotic sig-
nals, leading to tumor cell survival, although this issue
remains controversial (2, 8). The possible role of HBx in
the late stages of tumor progression and metastasis,
however, has not been established.
The spread of a primary tumor to a secondary metasta-
tic site requires cancer cells to be able to degrade the sur-
rounding ECM and invade the lymphatic and blood ves-
sels. Matrix metalloproteinases (MMPs) mediate ECM
remodeling and are involved in a variety of pathophysi-
ological processes, including tumor metastasis (9).
Degradation of collagen IV, a main component of the
basal lamina, is achieved by specific MMPs known as
gelatinases (MMP-2 and MMP-9). MMP-2/gelatinase A
is secreted as a proenzyme that is activated at the cell sur-
face by membrane-type 1 matrix metalloproteinase
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(MT1-MMP) (9). Expression of MT1-MMP and activa-
tion of MMP-2 are associated with tumor invasion and
metastasis and can be induced by different stimuli
(9–11). Interestingly, it has recently been shown that
expression of MT1-MMP and activation of MMP-2 can
be regulated by cyclooxygenase-2 activity (12).
Cyclooxygenases (COXs) mediate the synthesis of
prostaglandins from arachidonate (13). COX-1 shows a
constitutive expression in different cell types and is
involved in the homeostatic function of prostaglandins.
In contrast, COX-2 expression can be induced by a num-
ber of mitogenic, inflammatory, and pro-oncogenic
stimuli and plays a key role in a variety of processes,
including the onset of the inflammatory response,
mitogenesis, angiogenesis, and tumor progression and
metastasis (13). In this context, COX-2 is expressed in
several carcinomas, including HCC, and overexpression
of this enzyme in transgenic mice is sufficient to induce
tumorigenesis (13–15). In addition, a strong correlation
has been established between the use of nonsteroidal
anti-inflammatory drugs (NSAIDs) and a decreased
incidence of different cancers (13).
In this study we describe the ability of HBx to induce
tumor cell invasion, both in vivo and in vitro. This inva-
sive behavior is dependent on MT1-MMP and COX-2
activity. Moreover, HBx upregulates the expression of
COX-2, at both mRNA and protein levels. These results
demonstrate the ability of this viral protein to induce
tumor cell invasion and support a role for HBx in the
late steps of tumor development and metastasis.
Methods
Cell lines, antibodies, and reagents. CMX and CMO cells are
derivatives of Chang liver cells (CCL13; American Type
Culture Collection, Manassas, Virginia, USA) and con-
stitutively express low levels of HBx and the hygromycin
resistance gene, respectively (16–18). The hepatic origin
of Chang liver cells has been recently established by
microarray assays (19). Three different CMX clones were
used to rule out clone-specific results. 2.2.15 cells were
derived from the human hepatoma cell line HepG2 by
stably transfecting two head-to-tail copies of the HBV
genome (20). HBx expression in 2.2.15 and CMX cells
has been previously reported (16, 20). 4pX cells are sta-
ble transfectants, derived from the immortalized
murine hepatocyte cell line AML-12, in which HBx
expression can be induced by removing tetracycline for
24 hours (21). All the experiments were carried out in
the absence of FCS. The blocking anti–MT1-MMP
mAb’s LEM 2/15 and LEM 1/58 were described previ-
ously (22). Anti–MMP-2 and anti–MMP-9 were pur-
chased from R&D Systems Inc. (Minneapolis, Min-
nesota, USA). Anti–α-tubulin, HGF, acetylsalicylic acid
(ASA), indomethacin, and the tetracycline analogue
doxicycline were obtained from Sigma-Aldrich (St.
Louis, Missouri, USA) and anti-albumin from DAKO
A/S (Glostrup, Denmark). Anti–COX-2 and the COX-2
inhibitor NS398 were purchased from Alexis Corp. (San
Diego, California, USA), and anti–COX-1 was from
Santa Cruz Biotechnology Inc. (Santa Cruz, California,
USA). The MMP inhibitor BB-3103 was kindly provid-
ed by British Biotech (Oxford, United Kingdom).
Meloxicam was a kind gift from Innogenetics GmbH
(Heiden-Westfalen, Germany).
In vivo and in vitro invasion assays. In vivo invasion assays
using chick embryos were performed as previously
described (23). Briefly, 2 million cells were seeded onto
the upper part of the chorioallantoic membrane (CAM)
of a 9-day-old chick embryo and allowed to invade for
48 hours. Genomic DNA was extracted from the lower
part of the CAM, and the presence of human Alu
sequences was analyzed by quantitative PCR.
For in vitro invasion assays of CMO, CMX, HepG2,
and 2.2.15 cells, 1 mg of growth factor–reduced
Matrigel (Becton Dickinson Immunocytometry Sys-
tems, Mountain View, California, USA) was added to
the upper chamber of Transwells with 12-µm pores and
allowed to air-dry. After washing, 3 × 105 cells were seed-
ed onto the upper chamber. For 4pX cells, 0.4 mg of
Matrigel was air-dried on 8-µm-pore Transwells, and 
4 × 104 cells were seeded. Six hours later, 10 ng/ml HGF
was added to the lower chamber, and, where indicated,
an inhibitor (5 µM BB-3103, 100 µM NS398, 60 µg/ml
meloxicam, 60 µg/ml indomethacin, or 600 µg/ml ASA)
or 20 µg/ml mAb was added to both chambers. Cells
were allowed to invade the Matrigel for 48 hours, after
which the Transwells were fixed in 4% formaldehyde,
the gel was removed with a cotton swab, and the filters
were cut and stained with 4′,6-diamidine-2′-phenylin-
dole dihydrochloride (DAPI). The cells in eight different
fields were counted using a fluorescence microscope.
Each experiment was carried out in triplicate.
Western blot. A total of 3 × 105 cells were grown in
the absence of FCS and, where indicated, treated with
10–100 µM NS398, 60 µg/ml meloxicam, 60 µg/ml
indomethacin, or 600 µg/ml ASA. After 24 hours,
cells were lysed in 60 µl of Laemmli buffer, and both
lysates and supernatants were analyzed by Western
blot as described (18).
RT-PCR. Cells were grown for 24 hours in 0% FCS, RNA
was extracted, and the cDNA was obtained from 1 µg of
total RNA by reverse transcription. Quantitative PCR of
MT1-MMP and COX-2 was carried out in a LightCycler
(Roche Diagnostics GmbH, Mannheim, Germany) using
a SYBR Green kit (Roche Diagnostics GmbH) and two
specific primer sets (5′-AGGGGCGGTGAGCGCTGCTG-3′
and 5′-TCAGACCTTGTCCAGCAGGG-3′ for MT1-MMP;
5′-TTCAAATGAGATTGTGGGAAAATTGCT-3′ and 5′-AGAT-
CATCTCTGCCTGAGTATCTT-3′ for COX-2).
Plasmids, transfections and luciferase assays. The reporter
plasmids bearing different constructs of the human
COX-2 promoter linked to the luciferase reporter 
gene have been previously described (24). pSV-X and 
the control vector pSV-hygro bear the X gene and 
the hygromycin phosphotransferase gene, respectively, un-
der the control of the SV40 early enhancer/promoter 
(25). The pSH102C∆418 expression vector (a kind gift 
from Gerald Crabtree, Stanford University, Stanford, 
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California, USA) derives from pBJ5 and encodes a
nuclear factor of activated T cell–2 (NF-AT2) deletion
mutant (1-418) that functions as a dominant negative
for all NF-AT isoforms (25).
Transfections were carried out as previously report-
ed (25), using 0.1 µg of reporter plasmid, 4 µg of 
pSV-X or pSV-hygro, and, where indicated, 1 µg of
pSH102C∆418 or pBJ5, using the DOSPER liposo-
mal reagent (Roche Diagnostics GmbH, Mannheim,
Germany). After 6 hours, the medium was
removed and cells were grown in DMEM
with 2% FCS for 18 hours. Cells were lysed,
and luciferase activity was measured.
Results
HBx induces tumor cell invasion. To determine whether
HBx could induce tumor cell invasion, we used both in
vivo and in vitro approaches. In vivo cell invasion was
evaluated using a chick embryo invasion model in
which cells are studied for their ability to degrade the
embryo CAM and penetrate into the bloodstream (23).
CMX cells displayed an invasive capacity fourfold high-
er than that of the control CMO cells (Figure 1a). In
addition, 2.2.15 cells showed 7.9 times more invasive
potential than their parental HepG2 cells (Figure 1b).
In vitro cell invasion was determined using a Matrigel
invasion assay. CMX cells showed a 2.3-fold higher inva-
sion efficiency than CMO cells (Figure 1c), and, similar-
ly, 2.2.15 cells showed increased invasive capacity with
respect to HepG2 cells (Figure 1d), indicating that HBx
was able to induce cell invasion both in vivo and in vitro.
HBx-induced invasion correlates with increased expression
of activated MMP-2. To study the possible role of MMPs
in HBx-induced cell invasion, we first analyzed the
effect of the general MMP inhibitor BB-3103 on the
invasive capacity of CMX and CMO cells. Transwell
invasion assays performed in the presence of BB-3103
showed a decreased number of both CMX and CMO
cells in the bottom chamber of the Transwell (Figure
2a), suggesting the involvement of MMPs in the inva-
sion of the gel by these cells.
To further support the relation between MMP expres-
sion and cell invasion, we tested the activity of different
MMPs by zymography assays. As shown in Figure 2b,
only a 66-kDa band, likely corresponding to MMP-2,
was detected by gelatin zymography in the culture
supernatants of Chang liver and HepG2-derived cells.
No MMP activity was detected when casein was used as
substrate (data not shown), suggesting that no other
MMPs were being secreted. We then analyzed the pres-
ence of the gelatinases MMP-2 and MMP-9 by Western
blot both in the cell culture supernatants and in cell
extracts. An increased amount of the activated 62-kDa
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Figure 1
HBx induces tumor cell invasion in vivo and in vitro. (a and b) In vivo
invasion. CMO and CMX (a) or HepG2 and 2.2.15 (b) were analyzed
for their ability to invade the CAM of a chick embryo. The results are
expressed as percentage of human DNA (left) or as number of
intravasated cells (right). Experiments were carried out at least in
quadruplicate. (c and d) In vitro invasion. The invasive capacity of
CMO and CMX (c) or HepG2 and 2.2.15 (d) cells was tested using
Matrigel-coated Transwells. Cells in the underside of the filter were
stained, and eight independent fields were counted. The results are
expressed as the mean value ± SE of three independent points.
Figure 2
HBx-induced tumor cell invasion is dependent on metal-
loproteinase activity, and HBx upregulates activated
MMP-2 expression. (a) CMO and CMX cells were
allowed to invade a Matrigel-coated Transwell in the
presence of the MMP inhibitor BB-3103 or DMSO as a
control. The invasion was quantified as in Figure 1. (b)
Cells were grown for 24 hours in serum-free medium,
and gelatin zymography analysis of the cell culture super-
natants of PMA-stimulated human umbilical vein
endothelial cells (control) and the different hepatic cell
lines was performed. (c and d) CMO and CMX (c) or
HepG2 and 2.2.15 (d) cell lysates and supernatants were
analyzed for MMP-2 and MMP-9 expression by Western
blot. Anti–α-tubulin and anti-albumin mAb’s assure
equal protein load in all lanes.
MMP-2 isoform was found in CMX cell extracts com-
pared with CMO cells (Figure 2c), whereas the 66-kDa
proMMP-2 isoform was not detected in the cell extracts
(Figure 2c) unless the blot was overexposed (data not
shown). On the contrary, the 66-kDa form was the only
MMP-2 isoform found in cell culture supernatants,
although no significant differences in the expression of
this protein were observed between CMX and CMO
cells. Activated MMP-2 was also increased in 2.2.15 cell
extracts compared with HepG2 extracts (Figure 2d). A
variable amount of proMMP-2, which proved not to be
significant, could be observed in the cell culture super-
natants. MMP-9 was detected neither in the cell
extracts nor in the cell culture supernatants (Figure 2,
c and d). It is noteworthy that when supernatants were
concentrated more than fivefold, a small amount of
proMMP-9 could be observed, and this amount was
not different between CMX and CMO cells (our
unpublished data).
Increase in activated MMP-2 in HBx-expressing cell
extracts is dependent on MT1-MMP upregulation. To deter-
mine whether the activation of MMP-2 correlated with
an induction of MT1-MMP expression, we performed
Western blot studies. CMX cells showed
increased expression of MT1-MMP
when compared with CMO cells (Figure
3a), correlating with the induction of
activated MMP-2. Consistently, 2.2.15
cells also showed an increment in 
MT1-MMP expression compared with
HepG2 cells (Figure 3a). To explore the
involvement of MT1-MMP in the induc-
tion of cell invasion by HBx, we tested
the effect of the blocking anti–MT1-
MMP mAb LEM 1/58 (22) on the inva-
sive capacity of the different cell lines.
Blockade of the MT1-MMP catalytic site
resulted in a loss of invasive capacity by
CMX and 2.2.15 cells (Figure 3b). In
addition, inhibition of MT1-MMP activ-
ity resulted in a decrease of activated
MMP-2 in CMX cells (Figure 3c), as
assayed by Western blot, suggesting that
MT1-MMP played an important role in
the induction of tumor cell invasion and
MMP-2 activation by HBx. Accordingly,
an upregulation of MT1-MMP mRNA
was observed by quantitative RT-PCR
both in CMX cells and in Chang liver
cells transiently transfected with an HBx
expression vector (Figure 3d).
HBx-induced MT1-MMP expression and
tumor cell invasion are sensitive to COX-2
inhibitors. Next, we explored the effect of
different COX-2 inhibitors on HBx-
induced cell invasion. The COX-2–spe-
cific inhibitor NS398 blocked the induc-
tion of MMP-2 activation by HBx in a
dose-dependent manner, and this inhi-
bition could be reversed by the addition of
prostaglandin E2 (PGE2) (Figure 4a). In addition, treat-
ment of CMX and 2.2.15 cells with 100 µM NS398
resulted in a decrease of MT1-MMP expression, where-
as it had no effect on CMO or HepG2 cells (Figure 4b).
Analysis of MT1-MMP mRNA expression by quantita-
tive RT-PCR in CMX and CMO cells treated with 100
µM NS398 showed a clear inhibition of MT1-MMP
mRNA synthesis by CMX cells (Figure 4c), confirming
a role for COX-2 in the induction of MT1-MMP expres-
sion by HBx. In contrast, little or no decrease in 
MMP-2 mRNA was observed in CMX or CMO cells
(not shown). More interestingly, the invasive ability of
CMX, but not CMO, cells was dramatically decreased
in the presence of NS398 (Figure 4d). The addition of
PGE2 restored about 75% of the CMX cells’ invasive
capacity, strengthening the evidence of the involvement
of COX. In addition, the invasive capacity demonstrat-
ed by 2.2.15 cells was decreased by NS398 to the levels
presented by HepG2 cells (Figure 4d).
We further confirmed our results by using an HBx-
inducible hepatic cell line, 4pX cells, which express
HBx when tetracycline is removed from the culture
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Figure 3
HBx-mediated increase of activated MMP-2 and cell invasion is due to the induction
of MT1-MMP expression. (a) MT1-MMP expression was analyzed by Western blot in
CMO, CMX, HepG2, and 2.2.15 cells grown for 24 hours in the absence of serum.
(b) CMO, CMX, HepG2, or 2.2.15 cells were allowed to invade a Matrigel-coated
Transwell in the presence of the anti–MT1-MMP mAb LEM 1/58 or a control anti-
body. The invasion was quantified as in Figure 1. (c) CMO and CMX cells were incu-
bated for 24 hours in the presence of the anti–MT1-MMP blocking mAb LEM 1/58
or a control mAb, and the presence of MMP-2 in the cell lysates was analyzed by
Western blot. (d) The presence of MT1-MMP mRNA was studied by quantitative 
RT-PCR in CMO and CMX cells and in Chang liver cells (CHL) transiently transfect-
ed with an HBx-expression vector or a control plasmid.
medium (21). HBx expression resulted in an upregula-
tion of MT1-MMP as assayed by Western blot (Figure
4b, right panel). This induction of MT1-MMP expres-
sion was prevented by the addition of the COX-2
inhibitor NS398. Moreover, removal of tetracycline
resulted in an increased invasive capacity (Figure 4d).
Again, inhibition of COX-2 prevented the enhance-
ment of 4pX cells’ invasive capacity.
We then studied the effect of different NSAIDs that
preferentially inhibit COX-2, COX-1, or both (meloxi-
cam, indomethacin, and ASA, respectively) on metal-
loproteinase production and tumor cell invasion
induced by HBx. Treatment of CMX cells with meloxi-
cam resulted in both a downregulation of MMP-2
activation and MT1-MMP expression (Figure 5a) and
a strong inhibition (50%) of their invasive potential
(Figure 5b). ASA showed a moderate inhibitory effect
on CMX cells, whereas indomethacin had no effect.
None of the NSAIDs showed a significant effect on
CMO cell invasion and metalloproteinase production.
Together, these results point to COX-2 as a key regu-
lator of the induction of MMP expression and cell
invasion by HBx.
HBx induces COX-2 expression. The blockade of cell inva-
sion and MMP expression by COX-2–specific inhibitors
prompted us to study whether HBx was inducing the
expression of COX-2. Western blot analysis of COX-2
and COX-1 revealed that CMX, 2.2.15, and 4pX cells
without tetracycline expressed higher COX-2 levels than
their respective control cells, whereas COX-1 was not
detected (Figure 6a). Quantitative RT-PCR analysis of
COX-2 confirmed the induction of enzyme in CMX cells
and in Chang liver cells transiently transfected with the
HBx expression vector pSV-X (Figure 6b). No differences
were observed in the transcript levels of mPGES, cPGES,
or COX-1 between CMX and CMO cells (data not
shown). In addition, we found a twofold increase in the
secretion of PGE2 by HBx-bearing cells that was blocked
by the addition of 10 µM NS398 (not shown). These
results demonstrate that HBx is able to induce COX-2
expression in independent hepatic cell lines.
HBx activates the COX-2 promoter in an NF-AT–dependent
manner. To explore the transcriptional regulation of the
COX-2 gene by HBx, we transfected Chang liver cells
with a luciferase-derived reporter construct bearing the
COX-2 promoter (positions –1796 to +104), along with
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Figure 4
Induction of MMP-2 activation, MT1-MMP expression, and cell invasion by HBx is sensitive to the COX-2 inhibitor NS398. (a) For 24
hours, CMX cells were grown in the presence of increasing amounts, and HepG2 and 2.2.15 cells were grown in the presence of 100 µM,
of the COX-2–specific inhibitor NS398, along with 10 µM PGE2 where indicated. The presence of activated MMP-2 in the cell lysates was
analyzed by Western blot. (b) CMO, CMX, HepG2, and 2.2.15 cells, as well as 4pX cells in which HBx expression was induced by remov-
ing tetracycline (Tet) for 24 hours, were treated or not treated with 100 µM NS398 for 24 hours and lysed, and the amount of MT1-MMP
protein was studied by Western blot. (c) CMX and CMO cells were treated or not treated with 100 µM NS398 for 24 hours, and the expres-
sion of MT1-MMP transcripts was analyzed by quantitative RT-PCR. (d) CMO, CMX, HepG2, 2.2.15, or 4pX cells (with or without tetra-
cycline) were allowed to invade Matrigel-coated Transwells in the presence of 100 µM NS398, or DMSO as a control, and 10 µM PGE2
where indicated. Cells that migrated to the lower chamber were quantified as in Figure 1.
increasing amounts of the HBx-expression vector 
pSV-X. As shown in Figure 7a, HBx was able to activate
the COX-2 promoter in a dose-dependent manner.
Similarly, HBx induced the COX-2 promoter when
transfected into HepG2 cells (Figure 7a). Deletion of
the region spanning positions –1796 to –170 of the
COX-2 promoter or point mutation of the proximal
NF-κB site had no effect on the activation of the pro-
moter by HBx. On the contrary, site-directed mutagen-
esis of the distal and proximal NF-AT sites resulted in
a 20% and a 50% loss of the HBx-induced promoter
activity, respectively (Figure 7b). Moreover, double
mutation of both NF-AT sites almost completely abol-
ished the activation of the promoter by HBx.
To further demonstrate the involvement of NF-AT in
the HBx-mediated transactivation of the COX-2 pro-
moter, we added a dominant negative NF-AT expres-
sion vector to the transfection system, which resulted
in a 50% inhibition of the COX-2 promoter activation
by HBx (Figure 7c). In contrast, transfection of a wild-
type NF-AT expression vector showed a strong syner-
gism with HBx in the activation of the COX-2 promot-
er. Our results demonstrate that NF-AT, but not
NF-κB, is necessary for the induction of COX-2 by HBx.
Discussion
Intrahepatic metastasis is a main cause of HCC recur-
rence and poor prognosis after tumor resection (1).
Although chronic infection by HBV is responsible for
the development of most HCCs, the specific role of
HBV proteins in HCC progression is unknown (1). In
this work, we provide evidence, for the first time to our
knowledge, that HBx, often the only viral protein
expressed by transformed hepatocytes (2, 3), induces
cell invasion, suggesting its involvement in the
metastatic spreading and recurrence of hepatic tumors.
We present both in vivo and in vitro results that sup-
port the ability of HBx to induce tumor cell invasion.
The chick embryo CAM invasion assay showed that
HBx increases the capacity of tumor cells to degrade
the ECM, cross the endothelial barrier, and reach the
bloodstream. This upregulation of the metastatic abil-
ities of tumor cells was corroborated by the Matrigel
invasion assays, in which HBx-expressing cells also dis-
played increased invasive potential.
Cancer cell invasion requires degradation of the base-
ment membrane, composed mainly of collagen IV,
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Figure 5
Effect of different NSAIDs on MMP-2 activation, MT1-MMP expres-
sion, and tumor cell invasion induced by HBx. (a) CMO and CMX
cells were grown for 24 hours in the presence of 60 µg/ml
indomethacin, 60 µg/ml meloxicam, 600 µg/ml ASA, or DMSO as a
control, and the amount of activated MMP-2 and MT1-MMP was
analyzed by Western blot. (b) CMX and CMO cells were allowed to
invade a Matrigel-coated Transwell in the presence of 60 µg/ml
indomethacin, 60 µg/ml meloxicam, 600 µg/ml ASA, or DMSO. Cells
that migrated to the lower chamber were quantified as in Figure 1.
Figure 6
HBx induces COX-2 expression. (a) The expression of COX-2 and
COX-1 was evaluated by Western blot in CMO, CMX, HepG2,
2.2.15, and 4pX cells (treated or not treated with tetracycline). (b)
The presence of COX-2 mRNA was analyzed by quantitative RT-PCR
in CMO and CMX cells, and in Chang liver cells transiently trans-
fected with pSV-X or the control vector pSV-hygro.
which is mediated by MMP-2 and MMP-9 (9). Most of
the MMP-2 found in the hepatic tumor is produced by
the hepatic stellate cells in the surrounding stroma and
is secreted as an inactive precursor (11). Although some
activated MMP-2 can be found in the fibrotic liver, the
highest MMP-2 activation efficiency is found in tumor
tissues (11) and correlates with MT1-MMP expression
and tumor spreading (9, 10). In this regard, MT1-MMP
is overexpressed in highly invasive HCCs (10), and acti-
vation of MMP-2 is associated with tumor progression
and recurrence in HCC patients (11). Moreover, 
MT1-MMP is also capable of activating other MMPs
and directly degrading ECM components and mem-
brane receptors (9, 26). This capacity has a pronounced
effect on cellular invasiveness independently of 
MMP-2 processing (26, 27). Thus, the induction of
MT1-MMP expression by HBx provides the cell with a
powerful invasive tool that contributes to tumor
spreading and may play a key role in HCC recurrence.
NSAIDs show antineoplastic activity in a number of
malignancies, due to their ability to inhibit the synthe-
sis of prostaglandins by COX-2 (13). Expression of this
enzyme is sufficient to induce tumor growth and inva-
sion by a variety of mechanisms (13), some of which 
are shared by HBx (2). In this regard, COX-2 enhances 
cell migration, expression of MT1-MMP, and MMP-2 
activation (12). HBx is also capable of inducing cell
motility (17), and we show herein that it upregulates
MMP-2 activation and MT1-MMP expression. Both
COX-2–dependent invasion and HBx-induced migra-
tion are mediated by CD44 (17, 28), which is cleaved by
MT1-MMP (26). Thus, by regulating COX-2, 
MT1-MMP, and CD44, HBx may be activating a com-
plex mechanism that will eventually lead to cell invasion.
COX-2–expressing cells induce neovascularization
by upregulating different proangiogenic enzymes
and growth factors, such as inducible nitric oxide
synthase (iNOS), TGF-β, and VEGF (29). HBx itself
induces the expression of iNOS, TGF-β, and VEGF,
and an angiogenic effect of this viral protein has been
proposed (30, 31). Moreover, COX-2 expression
results in increased apoptosis resistance (13), anoth-
er property shared by HBx in certain systems (8).
Thus, the induction of COX-2 expression by HBx
may help to explain the variety of pro-oncogenic
effects of this viral protein and may unveil a new tar-
get for the treatment of HBV-derived HCC.
Interestingly, NSAID and NS398 treatment of Chang
liver and HepG2 cells results in increased response to
IFN-α, suggesting that COX-2 expression may result in
IFN therapy resistance (32). In this context, the induc-
tion of COX-2 by HBx would help the virus to evade the
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Figure 7
HBx induces the COX-2 promoter in an
NF-AT–dependent manner. (a) Chang
liver and HepG2 cells were transfected
with 0.1 µg of the luciferase-based COX-2
reporter plasmid P2-1900 (–1796 to
+104) along with increasing amounts (in
Chang liver) or 5 µg (in HepG2) of pSV-X.
The amount of luciferase was analyzed 18
hours later, and the results were expressed
as fold induction over the value without
pSV-X. (b) Chang liver cells were trans-
fected as in a with reporter plasmids con-
taining different deletions and point
mutations of the COX-2 promoter, along
with 5 µg of pSV-X or pSV-hygro. The
results are expressed as fold induction over
the value without pSV-X for each promot-
er construct and are representative of four
independent experiments. (c) Chang liver
cells were transfected as in a with 5 µg of
pSV-X or pSV-hygro and 1 µg of the dom-
inant negative NF-AT expression vector
pSH102C∆418, an NF-AT2 wild-type
(NF-ATwt) expression vector, or the empty
vector pBJ5 as a negative control. The val-
ues are expressed as fold induction over
the value with pBJ5 and without pSV-X.
Results are representative of at least three
independent experiments.
immune system, favoring chronic HBV infection and
the progression to cirrhosis and HCC.
COX-2 expression can be induced by a number of
mitogenic, inflammatory, and pro-oncogenic stimuli
(13). It has been recently reported that the calcium-reg-
ulated transcription factor NF-AT is essential for the
activation of COX-2 transcription by VEGF or PMA plus
calcium ionophore (24), whereas activation by LPS or
TNF-α is mediated by NF-κB (13). Our results demon-
strate that NF-AT, but not NF-κB, is necessary for the
induction of COX-2 by HBx. We have previously shown
that HBx activates NF-AT in a calcineurin-dependent
manner (25), which is likely due to the increase in intra-
cellular calcium and oxidative stress generated after the
interaction of HBx with the mitochondrion (33, 34).
These results suggest a role for NF-AT, oxidative stress,
and calcium signaling in the induction of inflammato-
ry mediators and tumor development.
In conclusion, our results suggest that the expression
of HBx provides tumor cells with metastatic potential.
Since HBx is still expressed after HCC development, we
propose that this viral protein may not only have a role
in carcinogenesis, as is currently believed, but may also
be responsible for tumor recurrence that results from
intrahepatic metastasis. The mechanisms described
herein by which HBx induces cell invasion, namely
induction of COX-2 and MT1-MMP expression and
activity, are in agreement with our previous findings
reporting that HBx induces cell migration, disruption of
intercellular adhesion, and cell-matrix interactions and
cytoskeleton rearrangements (16–18). The involvement
of HBx in tumor spreading represents a new finding in
the contribution of the hepatitis B virus to HCC and
provides new clues for understanding the role of HBx
after tumor establishment, unveiling potential new tar-
gets in the therapy against this aggressive malignancy.
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